[go: up one dir, main page]

WO2009087379A3 - Composés - Google Patents

Composés Download PDF

Info

Publication number
WO2009087379A3
WO2009087379A3 PCT/GB2009/000039 GB2009000039W WO2009087379A3 WO 2009087379 A3 WO2009087379 A3 WO 2009087379A3 GB 2009000039 W GB2009000039 W GB 2009000039W WO 2009087379 A3 WO2009087379 A3 WO 2009087379A3
Authority
WO
WIPO (PCT)
Prior art keywords
piperidin
amino
alkyl
methyl
methylpyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2009/000039
Other languages
English (en)
Other versions
WO2009087379A2 (fr
Inventor
Martin Quibell
John Paul Watts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amura Therapeutics Ltd
Original Assignee
Amura Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0800338A external-priority patent/GB0800338D0/en
Priority claimed from GB0808669A external-priority patent/GB0808669D0/en
Application filed by Amura Therapeutics Ltd filed Critical Amura Therapeutics Ltd
Priority to JP2010541840A priority Critical patent/JP5587790B2/ja
Priority to EP09700614.2A priority patent/EP2240491B1/fr
Publication of WO2009087379A2 publication Critical patent/WO2009087379A2/fr
Publication of WO2009087379A3 publication Critical patent/WO2009087379A3/fr
Priority to US12/823,558 priority patent/US8501744B2/en
Anticipated expiration legal-status Critical
Priority to US13/901,479 priority patent/US9045492B2/en
Priority to US14/683,913 priority patent/US20150209349A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)

Abstract

L'invention porte sur un composé de formule (I), ou sur un sel, un hydrate, un complexe ou un promédicament pharmaceutiquement acceptable de celui-ci. Dans la formule, R1 ou R2 représente H et R2 ou R1 est choisi parmi alkyle en C1-8, cycloalkyle en C3-6 et alkyl en C1-8-aryle en C5-10; R est choisi parmi tert-butylméthyle, isopropylméthyle, sec- butyle, tert-butyle, cyclopentyle, cyclohexyle et 1-méthylcyclopentyle; R est choisi parmi ce qui suit : où : R4 est choisi parmi alkyle en C1-8 et cycloalkyle en C3-8; G est choisi parmi : )CH, )CMe et N; E est choisit parmi O, S, ) SO2, )NH, )NMe et N-oxyde ()N->O); J et R sont choisis indépendamment parmi : )CH, N et N-oxyde ()N-^O); et R41 est choisi parmi amino, méthylamino, diméthylamino, isopropylamino, isopropyl(méthyl)amino, cyclopropylamino, cyclopropyl(méthyl)amino, cyclopentylamino, morpholino, pipéridin-1-yle, pipéridin-1-ylméthyle, morpholinométhyle, 4-méthylpipérazin-l-yle, 4-(2-méthoxyéthyl)pipérazin-l-yle, 1- morpholinoéthyle, l-(diméthylamino)éthyle, l-(méthylamino)éthyle, 4-fluoro-l-méthylpyrrolidin-2-yle, 4,4-difluoropipéridin-l-yle, pipéridin-4-yle, l-méthylpipéridin-4-yle, pyridin-3-ylamino, pyridin-2-ylamino, l-méthylpyrrolidin-3-yle, méthyle, isopropyle. L'invention porte également sur des compositions pharmaceutiques comprenant des composés de formule (I) et sur l'utilisation de ces composés dans le traitement de diverses maladies.
PCT/GB2009/000039 2008-01-09 2009-01-07 Composés Ceased WO2009087379A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2010541840A JP5587790B2 (ja) 2008-01-09 2009-01-07 化合物
EP09700614.2A EP2240491B1 (fr) 2008-01-09 2009-01-07 DÉRIVÉS DE TÉTRAHYDROFURO(2,3-b)PYRROL-3-ONE COMME INHIBITEURS DE CYSTÉINE PROTÉINASES
US12/823,558 US8501744B2 (en) 2008-01-09 2010-06-25 Piperazine compounds
US13/901,479 US9045492B2 (en) 2008-01-09 2013-05-23 Piperazine compounds
US14/683,913 US20150209349A1 (en) 2008-01-09 2015-04-10 Piperazine Compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0800338A GB0800338D0 (en) 2008-01-09 2008-01-09 Compounds
GB0800338.6 2008-01-09
GB0808669A GB0808669D0 (en) 2008-05-13 2008-05-13 Compounds
GB0808669.6 2008-05-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/823,558 Continuation US8501744B2 (en) 2008-01-09 2010-06-25 Piperazine compounds

Publications (2)

Publication Number Publication Date
WO2009087379A2 WO2009087379A2 (fr) 2009-07-16
WO2009087379A3 true WO2009087379A3 (fr) 2009-09-03

Family

ID=40791443

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/000039 Ceased WO2009087379A2 (fr) 2008-01-09 2009-01-07 Composés

Country Status (4)

Country Link
US (3) US8501744B2 (fr)
EP (2) EP2240491B1 (fr)
JP (1) JP5587790B2 (fr)
WO (1) WO2009087379A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540391B2 (en) 2013-01-17 2017-01-10 Sanofi Isomannide derivatives as inhibitors of soluble epoxide hydrolase

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU581929B2 (en) * 1985-09-16 1989-03-09 Schering Corporation Antihypertensive agents, pharmaceutical compositions containing them and processes for the preparation of the agents and compositions
GB0817424D0 (en) 2008-09-24 2008-10-29 Medivir Ab Protease inhibitors
NZ704666A (en) 2012-08-23 2018-05-25 Alios Biopharma Inc Compounds for the treatment of paramoxyvirus viral infections
CN114716426A (zh) * 2013-08-21 2022-07-08 詹森生物制药有限公司 抗病毒化合物
WO2015038655A1 (fr) 2013-09-12 2015-03-19 Alios Biopharma, Inc. Composés d'aza-pyridone et leurs utilisations
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057270A1 (fr) * 2001-01-17 2002-07-25 Amura Therapeutics Limited Inhibiteurs de la cruzipaine et autres cysteines proteases
WO2005066180A1 (fr) * 2004-01-08 2005-07-21 Medivir Ab Inhibiteurs de cysteine protease
WO2008007114A1 (fr) * 2006-07-14 2008-01-17 Amura Therapeutics Limited Tétrahydrofuro[3,2-b]pyrrol-3-ones et leur utilisation comme inhibiteurs de la cathepsine k
WO2008007107A1 (fr) * 2006-07-14 2008-01-17 Amura Therapeutics Limited Composés

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3444216A (en) 1966-11-16 1969-05-13 Upjohn Co Process for the oxidation of primary and secondary alcohols
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US5128448A (en) 1990-01-10 1992-07-07 Hoffman-La Roche Inc. CCK analogs with appetite regulating activity
US5374623A (en) 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use
CA2111930A1 (fr) 1992-12-25 1994-06-26 Ryoichi Ando Derives d'aminocetones
DZ2285A1 (fr) 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
US6043218A (en) 1996-10-22 2000-03-28 Medical University Of South Carolina Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides
AR013079A1 (es) 1997-05-06 2000-12-13 Smithkline Beecham Corp Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
PL202226B1 (pl) 1997-11-05 2009-06-30 Novartis Ag Nitryl dipeptydowy, jego zastosowanie lecznicze i zawierająca go kompozycja farmaceutyczna
GB9806287D0 (en) 1998-03-24 1998-05-20 Synphar Lab Inc Monobactam enzyme inhibitors
MA26618A1 (fr) 1998-04-09 2004-12-20 Smithkline Beecham Corp Composes et compositions pharmaceutiques pour le traitement du paludisme
DZ2815A1 (fr) 1998-06-12 2003-12-01 Smithkline Beecham Corp Inhibiteurs de protéase.
JP2003527819A (ja) 1998-08-14 2003-09-24 スミスクライン・ビーチャム・コーポレイション カテプシンｋの阻害方法
ES2142773B1 (es) 1998-10-07 2001-01-01 Lacer Sa Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia desminuida.
CO5150165A1 (es) 1998-11-13 2002-04-29 Smithkline Beecham Plc Inhibidores de proteasa: tipo catepsina k
EP1155010A1 (fr) 1999-02-20 2001-11-21 AstraZeneca AB Derives acetamido acetonitriles en tant qu'inhibiteurs de la cathepsine l et/ou s
GB9903861D0 (en) 1999-02-20 1999-04-14 Zeneca Ltd Chemical compounds
EP1155011A1 (fr) 1999-02-20 2001-11-21 AstraZeneca AB Derives nitriles di- et tripeptidiques, utiles en tant qu'inhibiteurs des cathepsines l et s
JP2002538151A (ja) 1999-03-02 2002-11-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド カテプシンの可逆的インヒビターとして有用な化合物
TW200404789A (en) 1999-03-15 2004-04-01 Axys Pharm Inc Novel compounds and compositions as protease inhibitors
HUP0200503A3 (en) 1999-03-15 2005-06-28 Axys Pharmaceuticals Inc South N-cyanomethyl amides as protease inhibitors and pharmaceutical compositions containing them
CA2367348A1 (fr) 1999-03-15 2000-09-21 Axys Pharmaceuticals, Inc. Composes et compositions utilises comme inhibiteurs de protease
GB9907683D0 (en) 1999-04-06 1999-05-26 Synphar Lab Inc Substituted azetidin-2-ones as cysteine protease inhibitors
GB9911417D0 (en) 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
GB9917909D0 (en) 1999-07-31 1999-09-29 Synphar Lab Inc Cysteine protease inhibitors
WO2001009910A1 (fr) 1999-08-03 2001-02-08 Siemens Aktiengesellschaft Circuit de temporisation d'interruption pour un appareil de commutation electromecanique
DK1218372T3 (da) 1999-09-13 2003-10-20 Boehringer Ingelheim Pharma Nye heterocykliske forbindelser, der er anvendelige som reversible inhibitorer af cysteinproteaser
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
AU7490900A (en) 1999-09-16 2001-04-17 Axys Pharmaceuticals, Inc. Chemical compounds and compositions and their use as cathepsin s inhibitors
GB9925264D0 (en) 1999-10-26 1999-12-29 Zeneca Ltd Chemical compounds
JP2003513921A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテア−ゼ阻害剤
JP2003513928A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
CN1240681C (zh) 1999-12-24 2006-02-08 霍夫曼-拉罗奇有限公司 作为组织蛋白酶k抑制剂的腈衍生物
CA2396257A1 (fr) 2000-01-06 2001-07-12 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Nouveaux composes et compositions utilises comme inhibiteurs de protease
GB0003111D0 (en) 2000-02-10 2000-03-29 Novartis Ag Organic compounds
WO2001068645A2 (fr) 2000-03-15 2001-09-20 Axys Pharmaceuticals, Inc. Composes et compositions agissant comme inhibiteurs de proteines
CZ20023168A3 (cs) 2000-03-21 2003-02-12 Smithkline Beecham Corporation Inhibitory proteázy
CA2404630A1 (fr) 2000-04-06 2001-10-18 Merck Frosst Canada & Co. Inhibiteurs de proteases a cysteine de type cathepsines
CO5280093A1 (es) 2000-04-18 2003-05-30 Smithkline Beecham Corp Metodos de tratamiento
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
OA12288A (en) 2000-06-14 2003-12-12 Smithkline Beecham Corp Protease inhibitors.
AU2001286983A1 (en) 2000-09-01 2002-03-13 Smith Kline Beecham Corporation Method of treatment
AU2001250570A1 (en) 2000-10-19 2002-04-29 Naeja Pharmaceutical Inc, Dihydropyrimidine derivatives as cysteine protease inhibitors
US7064123B1 (en) 2000-12-22 2006-06-20 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
US6958358B2 (en) 2001-01-17 2005-10-25 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
WO2002080920A1 (fr) 2001-04-06 2002-10-17 Axys Pharmaceuticals, Inc. Arylacetamido-cetobenzoxazole comme inhibiteurs de la cysteine protease
WO2002092563A2 (fr) 2001-05-17 2002-11-21 Smithkline Beecham Corporation Inhibiteurs de protease
FR2826572B1 (fr) 2001-06-29 2005-10-07 Oreal Compositions contenant un derive d'hydroxydiphenyl ether inhibant le developpement des odeurs corporelles
JP2005504040A (ja) 2001-08-03 2005-02-10 スミスクライン ビーチャム コーポレーション カテプシンＫ阻害剤としてのα−ケトアミド誘導体
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
CN1324008C (zh) 2001-09-14 2007-07-04 安万特药物公司 作为组织蛋白酶抑制剂的新化合物和组合物
EP1434769A2 (fr) 2001-10-02 2004-07-07 Boehringer Ingelheim Pharmaceuticals Inc. Composes utiles comme inhibiteurs reversibles de cysteine protease
JP2005508979A (ja) 2001-10-29 2005-04-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド システインプロテアーゼの可逆性インヒビターとして有用な化合物
WO2003041649A2 (fr) 2001-11-13 2003-05-22 Merck Frosst Canada & Co. Derives cyanoalkylamino utilises comme inhibiteurs de la protease
KR20050044497A (ko) 2001-11-14 2005-05-12 아벤티스 파마슈티칼스 인크. 올리고펩티드 및 카텝신 ｓ 억제제로서 이를 포함하는조성물
CA2499465A1 (fr) 2002-07-16 2004-01-22 Amura Therapeutics Limited Composes a activite biologique
WO2006064286A1 (fr) 2004-12-13 2006-06-22 Medivir Uk Ltd Inhibiteurs de cathepsine s

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057270A1 (fr) * 2001-01-17 2002-07-25 Amura Therapeutics Limited Inhibiteurs de la cruzipaine et autres cysteines proteases
WO2005066180A1 (fr) * 2004-01-08 2005-07-21 Medivir Ab Inhibiteurs de cysteine protease
WO2008007114A1 (fr) * 2006-07-14 2008-01-17 Amura Therapeutics Limited Tétrahydrofuro[3,2-b]pyrrol-3-ones et leur utilisation comme inhibiteurs de la cathepsine k
WO2008007107A1 (fr) * 2006-07-14 2008-01-17 Amura Therapeutics Limited Composés

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
QUIBELL, MARTIN ET AL: "Bicyclic peptidomimetic tetrahydrofuro[3,2-b]pyrrol-3-one and hexahydrofuro[3,2-b]pyridin-3-one based scaffolds: synthesis and cysteinyl proteinase inhibition", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 12, no. 21, 2004, pages 5689 - 5710, XP002453778 *
See also references of EP2240491A2 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540391B2 (en) 2013-01-17 2017-01-10 Sanofi Isomannide derivatives as inhibitors of soluble epoxide hydrolase

Also Published As

Publication number Publication date
US8501744B2 (en) 2013-08-06
US20110077254A1 (en) 2011-03-31
US20130252969A1 (en) 2013-09-26
WO2009087379A2 (fr) 2009-07-16
JP2011509282A (ja) 2011-03-24
US9045492B2 (en) 2015-06-02
EP2240491A2 (fr) 2010-10-20
US20150209349A1 (en) 2015-07-30
EP2240491B1 (fr) 2015-07-15
EP2719700A1 (fr) 2014-04-16
JP5587790B2 (ja) 2014-09-10

Similar Documents

Publication Publication Date Title
WO2009087379A3 (fr) Composés
MX2009006401A (es) Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
TW200621762A (en) Novel compounds
WO2021012049A8 (fr) Dérivés 2-morpholinopyridine substitués utilisés en tant qu'inhibiteurs de kinases atr
MY143206A (en) 1h-thieno 2,3-c pyrazole derivatives useful as kinase i inhibitors
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
NZ708563A (en) Treatment of cancers using pi3 kinase isoform modulators
WO2007127635A3 (fr) Dérivés de dicéto-pipérazine et pipéridine en tant qu'agents antiviraux
WO2008002245A8 (fr) Nouveaux composés 385
JP2009541223A5 (fr)
PH12013501594A1 (en) Substituted indazole derivatives active as kinase inhibitors
SI1678166T1 (sl) Inhibitorji proteinske kinaze
WO2007040438A3 (fr) Derives d'imidazo(4,5-b) pyridine utilises comme inhibiteurs de la glycogene synthase kinase 3 pour le traitement de la demence et de troubles neurodegeneratifs
GB0112348D0 (en) Compounds
SI2324008T1 (sl) 3,4-diarilpirazoli kot protein-kinazni inhibitorji
NZ596125A (en) Checkpoint kinase 1 inhibitors for potentiating dna damaging agents
WO2008002244A8 (fr) Nouveaux composés 384
WO2008023258A8 (fr) Dérivés de pipéridine
JP5634510B2 (ja) イミノ糖ならびにブニヤウイルスおよびトガウイルス疾患を治療する方法
ES2579628T3 (es) Iminoazúcares y métodos de tratamiento de enfermedades virales
MX2007013624A (es) Inhibidores de proteina cinasa.
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
TW200745136A (en) 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives
EA200601418A1 (ru) ПРОИЗВОДНЫЕ 1Н-ТИЕНО [2,3-с] ПИРАЗОЛА, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ИСПОЛЬЗОВАНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09700614

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010541840

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009700614

Country of ref document: EP